FDFT1 is significantly upregulated in ovarian cancer, prostate cancer, tongue squamous cell carcinoma, and glioma, in comparison to normal adjacent tissues (Nakae et al., 2021; Brusselmans et al., 2007; Chattopadhyay and Mallick, 2023; Facchini et al., 2018), whereas its expression is comparatively low in colon cancer, gastric cancer, and renal clear cell carcinoma (Weng et al., 2020; Zhao et al., 2021; Huang et al., 2022). Here, FDFT1 is linked to colonic neoplasm.